Supernus & Indivior Merge, Forming a Diversified CNS Biopharma Powerhouse
Supernus and Indivior merge into INDV, a diversified CNS biopharma with 11 products, $1B dividend, and a new CEO to accelerate neuroscience drug development.
- SUPERNUS PHARMACEUTICALS INC
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
2 minutes to read
